Zacks23h agobullish
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 ViewJazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
531last 24h
2512last 7d
479● bullish (7d)
255● bearish (7d)
197publishers
Stocktwits37d agobullish
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.
Zacks41d agobullish
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks49d agobullish
Is ABCELLERA BIOLG (ABCL) Outperforming Other Medical Stocks This Year?Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.
Zacks58d agobullish
Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 85.6% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Insider Monkey74d agobullish
Here’s Why AbCellera (ABCL) is Among the 10 Best Penny Stocks to Buy for Long TermAbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 12, 2026, Stifel raised the firm’s price target on AbCellera Biologics Inc. (NASDAQ:ABCL) to $8 from $7 and kept a Buy rating on the shares. The firm said preliminary safety, pharmacokinetic, and pharmacodynamic data from the […]
Zacks75d agobullish
Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks85d agobullish
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue EstimatesABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +36.36% and +68.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?